Memorandum
Today, Insulet announced the appointment of Dr. Jessica Hopfield to its Board of Directors. Dr. Hopfield currently serves as Vice Chair of Joslin’s Board of Directors; as an independent director of rEVO Biologics (a biotech focused on rare diseases); and as an independent consultant to start-up technology firms. She was previously an Associate and Partner at McKinsey in the Global Pharmaceuticals and Medical Products practice from 1995 to 2009. Her combined diabetes and healthcare experience should be a valuable asset as Insulet transitions to a new era. The company has seen tremendous leadership changes over the past 11 months, beginning with the retirement of CEO Duane DeSisto last September and culminating in a full changeover of the executive management team (under new CEO Patrick Sullivan) as of earlier this month with the resignation of COO Patrick Ryan and General Counsel R. Anthony Diehl. We look forward to the company’s 2Q15 update call on Thursday, particularly to hear the latest on the US OmniPod business. See our Insulet 1Q15 update as a pre-read!
-- by Adam Brown and Kelly Close